Notícias XOMA Royalty Corporation - XOMA | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
XOMA Royalty Corporation (XOMA)
XOMA Royalty Corporation (XOMA) Notícias

XOMA Royalty Corporation (XOMA)

26,50

0,02

(0,08%)

Fechado 30 Janeiro 6:00PM

Atrasado por 15 minutos

26,40

-0,10

(-0,38%)

Após o horário de negociação: 9:59PM

Atrasado por 15 minutos

Capacite seu portfólio: Discussões em tempo real e ideias de negociação acionáveis.

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty to Present at Upcoming Investor Conferences in September

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Declares Quarterly Preferred Stock Dividends

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

Actym Therapeutics Appoints Thomas Smart as CEO

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Short DAX X3 Total Return

Fidelity US Momentum Cur...

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições